Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Lewitzki, Victor ^a,d   Andratschke, Nicolaus ^a,b   Kuhnt, Thomas ^a,c   Hildebrandt, Guido ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Concomitant radiotherapy; Gefitinib; Radiation myelitis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DENOSUMAB; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GADOLINIUM; GEFITINIB; PACLITAXEL; PEMETREXED; PREGABALIN; STEROID; TAPENTADOL; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ADRENAL METASTASIS; AGED; ARTICLE; BACKACHE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CEREBELLUM INJURY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOLOGY; DIARRHEA; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; EXON; FECES INCONTINENCE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HEMATURIA; HIP PAIN; HUMAN; HUMAN TISSUE; LATENT PERIOD; LIVER METASTASIS; LOWER LEG; LUNG METASTASIS; MAINTENANCE THERAPY; MULTIMODALITY CANCER THERAPY; MUSCLE CONTRACTION; MUSCLE TONE; MUSCLE WEAKNESS; MYELITIS; NEUROLOGIC DISEASE; NEUROPATHY; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARALYSIS; PATHOLOGIC FRACTURE; PROPRIOCEPTION; RADIATION INJURY; SPINAL CORD; SPINAL CORD DISEASE; SPINAL CORD LESION; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; VERTEBRA; WEIGHT REDUCTION; ADVERSE EFFECTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG EFFECTS; LUNG NEOPLASMS; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION INJURIES; RADIATION RESPONSE; SECONDARY; SPINAL NEOPLASMS; THORACIC VERTEBRA;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MYELITIS; PALLIATIVE CARE; QUINAZOLINES; RADIATION INJURIES; SPINAL NEOPLASMS; THORACIC VERTEBRAE;

EID: 84924262007     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0334-7     Document Type: Article

References (22)

1. Macbeth FR, Wheldon TE, Girling DJ, Stephens RJ, Machin D, Bleehen NM, et al. Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer: the Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996;8:176-81.
2. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149-58.
3. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006;24:4517-20.
4. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res. 2008;14:1266-73.
5. Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010;5:1382-90.
6. Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int J Radiat Oncol Biol Phys. 2012;83:e43-52.
7. Park S-Y, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer. 2010;9:222.
8. Chen F-H, Fu S-Y, Yang Y-C, Wang C-C, Chiang C-S, Hong J-H. Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway. Int J Radiat Oncol Biol Phys. 2013;86:777-84.
9. Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol. 2008;3:250-7.
10. Supe SS, Ganesh KM, Naveen T, Jacob S, Sankar BN. Spinal cord response to altered fractionation and re-irradiation: radiobiological considerations and role of bioeffect models. J Cancer Res Ther. 2006;2:105-18.
11. Higashida T, Colen CB, Guthikonda M. Diagnostic and therapeutic strategy for confounding radiation myelitis. Clin Neurol Neurosurg. 2010;112:353-6.
12. Koehler PJ, Verbiest H, Jager J, Vecht CJ. Delayed radiation myelopathy: serial MR-imaging and pathology. Clin Neurol Neurosurg. 1996;98:197-201.
13. Schultheiss TE. The radiation dose-response of the human spinal cord. Int J Radiat Oncol Biol Phys. 2008;71:1455-9.
14. Adamus-Gorka M, Brahme A, Mavroidis P, Lind BK. Variation in radiation sensitivity and repair kinetics in different parts of the spinal cord. Acta Oncol. 2008;47:928-36.
15. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10-9.
16. Dunst J, Gebhart E. Unexpected tumor response, radiation myelitis and increased in vitro-radio-sensitivity of lymphocytes in a patient with non-small lung cancer. Radiother Oncol. 1995;36:158.
17. Mahta A, Borys E, Kanakamedala MR, Kesari S. Radiation induced myelopathy in a patient with tongue cancer: a case report. Acta Oncol. 2012;51:409-11.
18. Okada S, Okeda R. Pathology of radiation myelopathy. Neuropathology. 2001;21:247-65.
19. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15:1042-7.
20. Iivanainen E, Lauttia S, Zhang N, Tvorogov D, Kulmala J, Grenman R, et al. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvasc Res. 2009;78:278-85.
21. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27:1864-71.
22. Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46:3287-93.